Articles tagged with: Multiple Myeloma
News, Resources »
The majority of myeloma patients develop bone disease, which is caused by two main factors: stimulation of cells that break down bone and suppression of cells that make bone. Drugs that alter these processes have therapeutic potential for bone disease.
A biological pathway called RANKL is known to increase break down of bone. Scientists have developed an antibody called denosumab, which decreases bone destruction by blocking the RANKL pathway. One dose of denosumab reduces bone resorption for 90 days. Denosumab is currently in clinical trials; however,…
News »
Current Trends In Leukemia, Lymphoma, And Myeloma – Physicians’ Education Resource and the Lurie Cancer Center will be holding a symposium at the Robert H. Lurie Medical Research Center Baldwin Auditorium in Chicago on January 16, 2009. The symposium will update cancer treatment providers on information presented during hematology conferences in 2008. Developments will be discussed through presentations, interactive case discussions, and Q&A opportunities. For more information, visit the conference Web site.
The Beast Feast – Local celebrity, Outdoors Dan, will host this fundraising feast to be held on January 16, 2009, from 6 p.m. to 9 p.m. at the Stoney Creek Inn in Johnston, IA. All proceeds from the event, which features a wild game buffet and live entertainment, will benefit the Leukemia & Lymphoma Society (LLS). For more information, visit the LLS Web site.
Julia Walls Kiefer Marrow Donor Project – The Kiwanis Club of Winston-Salem, NC, is hosting a drive to find potential bone-marrow donors for myeloma patient Julia Kiefer and others who are in need of a transplant. The drive will be held on January 17, 2009, from 11 a.m. to 3 p.m. at College Park Baptist Church. The cheek swab test that determines whether a person is a potential donor costs $52, but funds are available to help anyone who cannot afford the test. For more information, visit the Winston-Salem Journal article.
Team In Training At P.F. Chang’s Rock ‘n’ Roll Arizona – This marathon event will take place on January 18, 2009. It begins at 7:30 a.m. in Phoenix and concludes that evening in Tempe. The Leukemia & Lymphoma Society’s charity sports organization, Team in Training, will be participating. For more information, visit the Rock ‘n’ Roll Arizona and LLS Web sites.
News, Resources »
Most myeloma patients suffer from bone disease, which can cause pain and fractures. Pain caused by bone disease is often treated with localized radiation therapy, and fractures can be stabilized by surgical procedures. However, these therapies only treat symptoms and do not actually slow or prevent further bone disease. Only bisphosphonates (BPs) are commonly used to prevent bone disease associated with myeloma.
BPs are a class of drugs that prevent bone from breaking down. This therapy can decrease bone pain and prevent the development of fractures, but it does not…
News »
Milestones In Myeloma – The Leukemia & Lymphoma Society (LLS) will hold a dinner program on January 13, 2009, from 6:30 p.m. to 8:30 p.m. at Johnny Carino’s restaurant in Austin, TX. Guest speaker Dr. Punit Chadha from Texas Oncology will discuss current and emerging myeloma drug therapies, management of disease and treatment-related side effects, and emotional aspects and support of myeloma. For more information, visit the LLS Web site.
Racial Disparities In Multiple Myeloma: Its Effects On The African-American Community – The Multiple Myeloma Research Foundation (MMRF) will hold a myeloma workshop on January 13, 2009, from 5:30 p.m. to 9 p.m. at the Hyatt Regency McCormick Place in Chicago. The meeting’s agenda is designed primarily to educate general practitioners and other health care professionals who treat patients with multiple myeloma. For more information, visit the MMRF Web site.
The Road To Recovery: Emerging Therapies In Blood Cancers – The Leukemia & Lymphoma Society (LLS) will hold a dinner program on January 15, 2009, from 5:30 p.m. to 7:30 p.m. at Tin Angel restaurant in Nashville, TN. Guest speaker Dr. Ian W. Flinn, Director of Hematologic Malignancies Research at the Sarah Cannon Research Institute, will speak about the process of new drug discovery, research, and approval for treatment; recent and ongoing advances in blood cancer treatments; and selecting a clinical trial as a possible treatment option. For more information, visit the LLS Web site.
News »
An oral anticancer agent, CX-4945, is now undergoing a Phase 1 clinical trial in patients with multiple myeloma, advanced solid tumors, or a disorder involving non-cancerous tumors called Castleman’s disease.
CX-4945 is first in its class of CK2 inhibitors. CK2 is an enzyme that plays a role in the development of cancerous cells through many cellular processes such as cell cycle regulation, signaling events between cells, blood vessel formation, inflammation, and cellular proliferation. Since CK2 is involved in many processes that lead to the development of cancerous cells, CX-4945…
